Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.53

€1.53

30.870%
0.36
30.870%
-
 
23.07.24 / Frankfurt WKN: A1T90L / Name: Diamyd Medical Ab / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Diamyd Medical Ab Stock

Diamyd Medical Ab dominated the market today, gaining €0.36 (30.870%).
For the coming years our community has positive and negative things to say abot the Diamyd Medical Ab stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.

Pros and Cons of Diamyd Medical Ab in the next few years

Pros
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-13

Upon initial review of the financial statements of Diamyd Medical Ab, it appears that the company has experienced some fluctuations in its financial performance over the past few years. The overall trend seems to be an increase in total assets and equity, while also experiencing some changes in cash flow and net income. A more detailed analysis is necessary to determine the strengths, weaknesses, and potential areas of improvement for the company.

Increasing Total Assets: Diamyd Medical Ab's total assets have grown from SEK 89.76 million in 2020 to SEK 236.52 million in 2022. This indicates that the company has been expanding its resources and investments, which may contribute to future growth.

Growing Stockholder Equity: The company's stockholder equity has also increased consistently over the past few years, from SEK 72.49 million in 2020 to SEK 214.38 million in 2022. This growth in stockholder equity signifies a strengthening of the company's financial position and may signal increased shareholder confidence.